Zoetis Inc. Stock

Equities

ZTS

US98978V1035

Pharmaceuticals

Real-time Estimate Cboe BZX 02:34:21 2024-05-09 pm EDT 5-day change 1st Jan Change
167.8 USD +1.78% Intraday chart for Zoetis Inc. +0.32% -15.00%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
Sales 2024 * 9.15B Sales 2025 * 9.77B Capitalization 75.25B
Net income 2024 * 2.51B Net income 2025 * 2.76B EV / Sales 2024 * 8.69 x
Net Debt 2024 * 4.31B Net Debt 2025 * 3.75B EV / Sales 2025 * 8.09 x
P/E ratio 2024 *
30.1 x
P/E ratio 2025 *
27.3 x
Employees 14,100
Yield 2024 *
1.05%
Yield 2025 *
1.19%
Free-Float 90.82%
More Fundamentals * Assessed data
Dynamic Chart
1 day-2.10%
1 week+4.05%
Current month+3.57%
1 month-0.46%
3 months-15.75%
6 months-3.48%
Current year-16.44%
More quotes
1 week
161.00
Extreme 161
172.23
1 month
144.80
Extreme 144.8
172.23
Current year
144.80
Extreme 144.8
200.53
1 year
144.80
Extreme 144.8
201.92
3 years
124.15
Extreme 124.1483
249.27
5 years
90.14
Extreme 90.14
249.27
10 years
30.24
Extreme 30.24
249.27
More quotes
Managers TitleAgeSince
Chief Executive Officer 52 11-12-31
Director of Finance/CFO 52 21-05-31
Chief Tech/Sci/R&D Officer - 10-12-31
Members of the board TitleAgeSince
Chairman 71 12-12-31
Director/Board Member 73 13-07-31
Director/Board Member 74 13-05-31
More insiders
Date Price Change Volume
24-05-09 167.9 +1.81% 1 286 938
24-05-08 164.9 -2.10% 4,673,075
24-05-07 168.4 +1.51% 3,337,509
24-05-06 166 -0.67% 3,081,343
24-05-03 167.1 -0.10% 3,007,125

Delayed Quote Nyse, May 08, 2024 at 04:00 pm EDT

More quotes
Zoetis Inc. specializes in developing, manufacturing and marketing of animal health products. Net sales break down by activity as follows: - pets (64.4%): cats and dogs (94.9% of net sales) and horses (5.1%); - livestock (34.5%): cattle (51.6% of sales), swine (20.2%), poultry (17.1%), fish (7.6%) and other (3.5%); - other (1.1%). Net sales break down by family of products into parasiticides (23%), vaccines (21.3%), dermatological products (16.4%), anti-infectives (13.4%), medical food additives (4.5%), diagnostic products (4.4%) and other (17%). At the end of 2022, the group has 29 production sites worldwide. The United States accounts for 53.4% of net sales.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
164.9 USD
Average target price
211 USD
Spread / Average Target
+27.93%
Consensus
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW